Lundbeck to divest non-strategic investments to the Lundbeck Foundation

29-Jan-2009 - H. Lundbeck A/S (Lundbeck) is selling its shares in the listed company LifeCycle Pharma A/S and ownership interests in four small private equity funds to the Lundbeck Foundation's investment and holding company LFI a/s. The transaction is the result of Lundbeck's decision to dispose of ...

LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate

LCP-Tacro Heads into US Phase II Clinical Trials for Organ Transplantation

04-Jun-2007 - LifeCycle Pharma A/S announced positive results from its Phase I clinical trial program of LCP-Tacro, a proprietary, once-daily tacrolimus tablet. A series of Phase I trials, involving more than 150 healthy volunteers demonstrate that LCP-Tacro has a once-daily profile, delivers consistently ...

LifeCycle Pharma Receives US Patent for its MeltDose Technology

18-May-2007 - LifeCycle Pharma A/S announced the issuance of a patent for its MeltDose® Technology by the US Patent and Trademark Office, US Patent No. 7,217,431. The patent covers the method of making a particulate material containing a drug substance with low aqueous solubility, using a unique controlled ...

LifeCycle Pharma Enters Three Distinct Strategic Collaboration Agreements With Global Pharmaceutical Companies

12-Oct-2006 - LifeCycle Pharma A/S announced that it has entered into three strategic collaboration agreements with Sandoz Inc. (an affiliate of Novartis AG), Merck Generics (a subsidiary of Merck KGaA of Darmstadt, Germany) and H. Lundbeck A/S. Sandoz and LifeCycle Pharma have entered into an exclusive ...